Entering text into the input field will update the search result below

Amgen shares topline data for Otezla in late-stage study for psoriasis

Dec. 01, 2021 4:39 PM ETAmgen Inc. (AMGN)By: Dulan Lokuwithana, SA News Editor2 Comments

Amgen(Applied Molecular Genetics Inc.) Capability Center in Tampa.

JHVEPhoto/iStock Editorial via Getty Images

  • Announcing topline data, Amgen (NASDAQ:AMGN) says that Otezla (apremilast) had met the primary endpoint in its Phase 3 DISCREET trial for adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.